



## NEWS RELEASE

### ANTARES PHARMA TO PRESENT AT UPCOMING INVESTOR CONFERENCES

**EWING, NJ (February 29, 2012)** – Antares Pharma, Inc. (NYSE Amex: AIS) today announced that Paul K. Wotton, Ph.D., President and Chief Executive Officer, will present at two upcoming investor conferences.

On Wednesday, March 7, 2012 at 9:20 a.m. ET (Eastern Time), Antares will present at the Cowen and Company 32<sup>nd</sup> Annual Health Care Conference.

On Tuesday, March 13, 2012 at 7:00 pm ET, Antares will present at the 24<sup>th</sup> Annual ROTH Conference.

Live webcasts of the presentations will be available via the “Investor Relations” page of the Antares website, [www.antarespharma.com](http://www.antarespharma.com). Replays of the webcasts will also be archived on Antares’ website for 90 days following the presentation.

#### **About Antares Pharma**

Antares Pharma focuses on self-injection pharmaceutical products and topical gel-based medicines. The Company's subcutaneous and intramuscular injection technology platforms include Vibex™ disposable pressure-assisted auto injectors, disposable multi-use pen injectors and Vision™ reusable needle-free injectors distributed as Tjet® and Zomajet® by Teva Pharmaceutical Industries, Ltd (Teva) and Ferring Pharmaceuticals (Ferring), respectively. In the injector area, Antares Pharma has a multi-product deal with Teva that includes Tev-Tropin® human growth hormone (hGH) and a partnership with Ferring that includes Zomacton® hGH. In the gel-based area, the Company's FDA approved product is Anturo® gel, an oxybutynin ATD™ gel for the treatment of OAB (overactive bladder) which has been licensed to Watson Pharmaceuticals, Inc. for the U.S. and Canada. Antares’ portfolio includes Elestrin® (estradiol gel) indicated for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, and marketed in the U.S. by Jazz Pharmaceuticals. Antares Pharma has two facilities in the U.S. The Parenteral Products Division located in Minneapolis, Minnesota directs the manufacturing and marketing of the Company’s reusable needle-free injection devices and related disposables, and develops its disposable pressure-assisted auto injector and pen injector systems. The Company’s corporate offices and Pharma Division are located in Ewing, New Jersey, where pharmaceutical products are developed utilizing both the Company’s transdermal systems and drug/device combination products.

#### **Contacts:**

Jack Howarth  
Vice President, Corporate Affairs  
609-359-3020 x133  
[jhowarth@antarespharma.com](mailto:jhowarth@antarespharma.com)

Westwicke Partners, LLC  
John Woolford  
(443) 213-0506  
[john.woolford@westwicke.com](mailto:john.woolford@westwicke.com)